Cargando…

In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles

BACKGROUND: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of GlaxoSmithKline plc) for the treatment of asthma and chronic ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shepherd, Thomas, Kennett, Matthew, Cooper, Andrew, Parkinson, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242708/ https://www.ncbi.nlm.nih.gov/pubmed/34726509 http://dx.doi.org/10.1089/jamp.2021.0017

Ejemplares similares

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler
por: Allan, Richard, et al.
Publicado: (2021)

Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus
por: Cooper, Andrew, et al.
Publicado: (2020)

Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma
por: Ng, Dik, et al.
Publicado: (2020)

Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD
por: Donohue, James F., et al.
Publicado: (2020)

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
por: Haughie, Scott, et al.
Publicado: (2020)

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(®) Dry Powder Inhaler
por: Prime, David, et al.
Publicado: (2015)

Vitamin D and responses to inhaled fluticasone in severe chronic obstructive pulmonary disease
por: Kunisaki, Ken M, et al.
Publicado: (2011)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

The future of inhalation therapy in chronic obstructive pulmonary disease
por: Cazzola, Mario, et al.
Publicado: (2022)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease
por: Çakmaklı, Seçil, et al.
Publicado: (2023)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
por: Park, Ji Won, et al.
Publicado: (2023)

Inhaler Technique and Adherence to Inhaled Medications among Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam
por: Ngo, Chau Quy, et al.
Publicado: (2019)

Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma
por: Hua, Jian-lan, et al.
Publicado: (2021)

Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study
por: Heerfordt, Christian Kjer, et al.
Publicado: (2023)

Improved inhaler handling after repeated inhalation guidance for elderly patients with bronchial asthma and chronic obstructive pulmonary disease
por: Usami, Osamu
Publicado: (2022)

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015)

Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease
por: Jakobsson, Jonas K F, et al.
Publicado: (2018)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease
por: Mahler, Donald A., et al.
Publicado: (2023)

Errors in inhaler use related to devices and to inhalation technique among patients with chronic obstructive pulmonary disease in primary health care
por: Lindh, Annika, et al.
Publicado: (2019)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

Inhalation in Pulmonary Tuberculosis
Publicado: (1886)

Inhalations in Pulmonary Diseases
Publicado: (1855)

Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease
por: Rodriguez-Roisin, Roberto, et al.
Publicado: (2016)

The Nurse Practitioners' Perspective on Inhaler Education in Asthma and Chronic Obstructive Pulmonary Disease
por: Scullion, Jane
Publicado: (2018)

Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
por: Humenberger, Magdalena, et al.
Publicado: (2018)

Chronic obstructive pulmonary disease caused by inhalation of dust: A meta-analysis
por: Peng, Cong, et al.
Publicado: (2020)

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?
por: Suissa, Samy
Publicado: (2020)

Is Inhaler Technique Associated with Quality of Life in Patients with Chronic Obstructive Pulmonary Disease?
por: Amini, Shahideh, et al.
Publicado: (2020)

The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited
por: Calverley, Peter
Publicado: (2021)

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective
por: Chan, Amy H. Y., et al.
Publicado: (2021)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

In Vitro Dosing Performance of the ELLIPTA(®) Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™)
por: Hamilton, Melanie, et al.
Publicado: (2015)

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
por: Siederer, Sarah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2od2rb5tlt0hqsj3p875osthop